<DOC>
	<DOC>NCT02743221</DOC>
	<brief_summary>The main purpose of this study is to evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for metastatic colorectal cancer in patients non-eligible for intensive therapy.</brief_summary>
	<brief_title>A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Written informed consent obtained. Male or Female participant aged â‰¥18 years old. Has ECOG performance status of 0, 1 or 2 at the time of the randomisation. Has definitive histologically or cytologically confirmed adenocarcinoma of the colon or rectum. RAS status must have been determined (mutant or wild). Has at least one measurable metastatic lesion. No previous anticancer therapy for metastatic colorectal cancer. Previous adjuvant (or neoadjuvant for patients with rectal cancer) chemotherapy is allowed only if if it has been completed more than 6 months before start of study treatment. Patient is not a candidate for combination chemotherapy with irinotecan or oxaliplatin, or for curative resection of metastatic lesions. Is able to take medication orally (i.e., no feeding tube). Has adequate organ function. Coagulation parameters in normal limit (or in therapeutic limit for patients treated with anticoagulant drugs). Women of childbearing potential must have been tested negative in a serum pregnancy test. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective method of birth control. Women and female partners using hormonal contraceptive must also use a barrier method. Is willing and able to comply with scheduled visits and study procedures. Foreseeable poor compliance to the study procedures. Is a pregnant or lactating female. Is inappropriate for entry into this study in the judgment of the Investigator. Has certain serious illness or serious medical condition(s) described in the protocol. Has had certain other recent treatment e.g. major surgery, field radiation, received investigational agent, within the specified time frames prior to randomisation. Has previously received S 95005 or history of allergic reactions attributed to compounds of similar composition to S 95005 or any of its excipients. Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption. Has contraindication to bevacizumab or capecitabine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>untreated</keyword>
	<keyword>first-line</keyword>
	<keyword>S95005</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>capecitabine</keyword>
</DOC>